Xilis is developing next generation technologies that provide a functional model of a patient’s individual tumor that can be directly tested for drug response, helping clinicians make timely treatment decisions for cancer patients and supporting drug development for world-leading pharmaceutical partners.

The company’s MicroOrganoSphereTM (MOS) technology and Precision Oncology Platform allows for rapid diagnostics, personalized patient care, and scalable patient-derived models for high-throughput drug discovery.